1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Human Hyperimmune Globulins Consumption 2016-2026 2.1.2 Human Hyperimmune Globulins Consumption CAGR by Region 2.2 Human Hyperimmune Globulins Segment by Type 2.2.1 Hepatitis B Immunoglobulins 2.2.2 Rabies Immunoglobulins 2.2.3 Tetanus Immunoglobulins 2.2.4 Others 2.3 Human Hyperimmune Globulins Sales by Type 2.3.1 Global Human Hyperimmune Globulins Sales Market Share by Type (2016-2021) 2.3.2 Global Human Hyperimmune Globulins Revenue and Market Share by Type (2016-2021) 2.3.3 Global Human Hyperimmune Globulins Sale Price by Type (2016-2021) 2.4 Human Hyperimmune Globulins Segment by Application 2.4.1 Government Institutions 2.4.2 Private Sector 2.4.3 Others 2.5 Human Hyperimmune Globulins Sales by Application 2.5.1 Global Human Hyperimmune Globulins Sale Market Share by Application (2016-2021) 2.5.2 Global Human Hyperimmune Globulins Revenue and Market Share by Application (2016-2021) 2.5.3 Global Human Hyperimmune Globulins Sale Price by Application (2016-2021) 3 Global Human Hyperimmune Globulins by Company 3.1 Global Human Hyperimmune Globulins Sales Market Share by Company 3.1.1 Global Human Hyperimmune Globulins Sales by Company (2019-2021) 3.1.2 Global Human Hyperimmune Globulins Sales Market Share by Company (2019-2021) 3.2 Global Human Hyperimmune Globulins Revenue Market Share by Company 3.2.1 Global Human Hyperimmune Globulins Revenue by Company (2019-2021) 3.2.2 Global Human Hyperimmune Globulins Revenue Market Share by Company (2019-2021) 3.3 Global Human Hyperimmune Globulins Sale Price by Company 3.4 Global Manufacturers Human Hyperimmune Globulins Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Human Hyperimmune Globulins Product Location Distribution 3.4.2 Players Human Hyperimmune Globulins Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 Human Hyperimmune Globulins by Region 4.1 Global Human Hyperimmune Globulins by Region 4.1.1 Global Human Hyperimmune Globulins Sales by Region 4.1.2 Global Human Hyperimmune Globulins Revenue by Region 4.2 Americas Human Hyperimmune Globulins Sales Growth 4.3 APAC Human Hyperimmune Globulins Sales Growth 4.4 Europe Human Hyperimmune Globulins Sales Growth 4.5 Middle East & Africa Human Hyperimmune Globulins Sales Growth 5 Americas 5.1 Americas Human Hyperimmune Globulins Sales by Country 5.1.1 Americas Human Hyperimmune Globulins Sales by Country (2016-2021) 5.1.2 Americas Human Hyperimmune Globulins Revenue by Country (2016-2021) 5.2 Americas Human Hyperimmune Globulins Sales by Type 5.3 Americas Human Hyperimmune Globulins Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Human Hyperimmune Globulins Sales by Region 6.1.1 APAC Human Hyperimmune Globulins Sales by Region (2016-2021) 6.1.2 APAC Human Hyperimmune Globulins Revenue by Region (2016-2021) 6.2 APAC Human Hyperimmune Globulins Sales by Type 6.3 APAC Human Hyperimmune Globulins Sales by Application 6.4 China 6.5 Japan 6.6 Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 7 Europe 7.1 Europe Human Hyperimmune Globulins by Country 7.1.1 Europe Human Hyperimmune Globulins Sales by Country (2016-2021) 7.1.2 Europe Human Hyperimmune Globulins Revenue by Country (2016-2021) 7.2 Europe Human Hyperimmune Globulins Sales by Type 7.3 Europe Human Hyperimmune Globulins Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Human Hyperimmune Globulins by Country 8.1.1 Middle East & Africa Human Hyperimmune Globulins Sales by Country (2016-2021) 8.1.2 Middle East & Africa Human Hyperimmune Globulins Revenue by Country (2016-2021) 8.2 Middle East & Africa Human Hyperimmune Globulins Sales by Type 8.3 Middle East & Africa Human Hyperimmune Globulins Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Country 9 Market Drivers, Challenges and Trends 9.1 Market Drivers and Impact 9.1.1 Growing Demand from Key Regions 9.1.2 Growing Demand from Key Applications and Potential Industries 9.2 Market Challenges and Impact 9.3 Market Trends 10 Marketing, Distributors and Customer 10.1 Sales Channel 10.1.1 Direct Channels 10.1.2 Indirect Channels 10.2 Human Hyperimmune Globulins Distributors 10.3 Human Hyperimmune Globulins Customer 11 Global Human Hyperimmune Globulins Market Forecast 11.1 Global Human Hyperimmune Globulins Forecast by Region 11.1.1 Global Human Hyperimmune Globulins Forecast by Regions (2021-2026) 11.2.2 Global Human Hyperimmune Globulins Revenue Forecast by Regions (2021-2026) 11.2 Americas Forecast by Countries 11.3 APAC Forecast by Region 11.4 Europe Forecast by Countries 11.5 Middle East & Africa Forecast by Countries 11.6 Global Human Hyperimmune Globulins Forecast by Type 11.7 Global Human Hyperimmune Globulins Forecast by Application 12 Key Players Analysis 12.1 CSL Behring 12.1.1 CSL Behring CSL Behring Company Information 12.1.2 CSL Behring Human Hyperimmune Globulins Product Offered 12.1.3 CSL Behring Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.1.4 CSL Behring Main Business Overview 12.1.5 CSL Behring Latest Developments 12.2 Grifols 12.2.1 Grifols Company Information 12.2.2 Grifols Human Hyperimmune Globulins Product Offered 12.2.3 Grifols Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.2.4 Grifols Main Business Overview 12.2.5 Grifols Latest Developments 12.3 Biotest 12.3.1 Biotest Company Information 12.3.2 Biotest Human Hyperimmune Globulins Product Offered 12.3.3 Biotest Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.3.4 Biotest Main Business Overview 12.3.5 Biotest Latest Developments 12.4 Kedrion 12.4.1 Kedrion Company Information 12.4.2 Kedrion Human Hyperimmune Globulins Product Offered 12.4.3 Kedrion Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.4.4 Kedrion Main Business Overview 12.4.5 Kedrion Latest Developments 12.5 CBPO 12.5.1 CBPO Company Information 12.5.2 CBPO Human Hyperimmune Globulins Product Offered 12.5.3 CBPO Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.5.4 CBPO Main Business Overview 12.5.5 CBPO Latest Developments 12.6 Emergent (Cangene) 12.6.1 Emergent (Cangene) Company Information 12.6.2 Emergent (Cangene) Human Hyperimmune Globulins Product Offered 12.6.3 Emergent (Cangene) Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.6.4 Emergent (Cangene) Main Business Overview 12.6.5 Emergent (Cangene) Latest Developments 12.7 Kamada 12.7.1 Kamada Company Information 12.7.2 Kamada Human Hyperimmune Globulins Product Offered 12.7.3 Kamada Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.7.4 Kamada Main Business Overview 12.7.5 Kamada Latest Developments 12.8 CNBG 12.8.1 CNBG Company Information 12.8.2 CNBG Human Hyperimmune Globulins Product Offered 12.8.3 CNBG Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.8.4 CNBG Main Business Overview 12.8.5 CNBG Latest Developments 12.9 Hualan Bio 12.9.1 Hualan Bio Company Information 12.9.2 Hualan Bio Human Hyperimmune Globulins Product Offered 12.9.3 Hualan Bio Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.9.4 Hualan Bio Main Business Overview 12.9.5 Hualan Bio Latest Developments 12.10 Shanghai RAAS 12.10.1 Shanghai RAAS Company Information 12.10.2 Shanghai RAAS Human Hyperimmune Globulins Product Offered 12.10.3 Shanghai RAAS Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.10.4 Shanghai RAAS Main Business Overview 12.10.5 Shanghai RAAS Latest Developments 12.11 Sichuan Yuanda Shuyang 12.11.1 Sichuan Yuanda Shuyang Company Information 12.11.2 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Product Offered 12.11.3 Sichuan Yuanda Shuyang Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.11.4 Sichuan Yuanda Shuyang Main Business Overview 12.11.5 Sichuan Yuanda Shuyang Latest Developments 12.12 ADMA Biologics 12.12.1 ADMA Biologics Company Information 12.12.2 ADMA Biologics Human Hyperimmune Globulins Product Offered 12.12.3 ADMA Biologics Human Hyperimmune Globulins Sales, Revenue, Price and Gross Margin (2019-2021) 12.12.4 ADMA Biologics Main Business Overview 12.12.5 ADMA Biologics Latest Developments 13 Research Findings and Conclusion
According to this latest study, the 2020 growth of Human Hyperimmune Globulins will have significant change from previous year. By the most conservative estimates of global Human Hyperimmune Globulins market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ xx million in 2019. Over the next five years the Human Hyperimmune Globulins market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2025.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Others
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Government Institutions
Private Sector
Others
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics
Summary:
Last updated on 13 January, 2021
Global Human Hyperimmune Globulins Market Growth 2021-2026
